Revvity, Inc. (NYSE:RVTY) reported second-quarter 2026 results that exceeded Wall Street expectations, prompting the health sciences company to raise its guidance for the full year.
The stronger-than-expected performance pushed Revvity shares 2.51% higher in pre-market trading following the earnings announcement.
Earnings and Revenue Beat Forecasts
The company posted adjusted earnings of $1.41 per share for the second quarter, comfortably ahead of the analyst consensus estimate of $1.21.
Revenue increased to $730 million, exceeding market expectations of approximately $703 million and representing a 1% increase from $720 million in the same quarter last year.
On a pro forma basis, excluding the China Immunodiagnostics business that is currently being divested, revenue totalled $711 million, up 4% year over year with pro forma organic growth of 3%.
Management Sees Improving Demand
President and Chief Executive Officer Prahlad Singh said the company experienced stronger demand across its customer base during the quarter.
“Revvity delivered a strong second quarter, with results above our expectations and encouraging signs of increased demand across our customer base,” said Prahlad Singh, president and chief executive officer of Revvity.
“As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth.”
Company Raises Full-Year Guidance
Revvity increased its full-year 2026 outlook and now expects pro forma revenue of between $2.83 billion and $2.86 billion.
The midpoint of $2.845 billion is broadly in line with the current analyst consensus estimate of approximately $2.83 billion.
The company also forecast pro forma organic revenue growth of between 4% and 5% for the year, alongside pro forma adjusted earnings per share of $5.30 to $5.40.
Diagnostics Business Leads Growth
The Diagnostics division delivered the strongest performance during the quarter.
Revenue increased 5% year over year to $371 million, with pro forma growth of 12% and pro forma organic growth of 11%.
Meanwhile, the Life Sciences segment generated revenue of $359 million, down 2% from the same period last year, while pro forma organic revenue declined 3%.
The company’s improved outlook and continued strength in its Diagnostics business helped reinforce investor confidence heading into the second half of 2026.
Revvity stock price
